■蒽醌类药物广泛应用于肿瘤的治疗。然而,多药耐药和严重的心脏毒性限制了其使用,这导致了新类似物的发现。在本文中,4-脱氧-ε-吡咯mycinone(4-Deo),属于蒽醌类化合物,作为一种新型的抗肿瘤药物或先导化合物,首次对其体内外抗肿瘤作用和安全性进行了研究。
■通过UV方法建立了4-Deo的定量分析。通过H22、HepG2和Caco2的细胞毒性实验评价4-Deo在体外的抗癌作用,并从细胞凋亡和周期等方面探讨其抗癌机制。通过皮下接种H22细胞建立荷瘤小鼠模型,评价4-Deo的体内抗肿瘤作用。通过健康细胞的体外安全性实验和H22荷瘤小鼠的体内安全性实验验证了4-Deo的安全性。肿瘤组织切片用CRT标记,用免疫组织化学方法初步探讨HMGB1、IL-6和CD115的抗癌机制。
■体外实验表明,4-Deo可以通过诱导细胞坏死和阻断S期细胞来抑制H22的生长,4-Deo对健康细胞的损害较小。体内实验表明,4-Deo增加了CRT和HMGB1的阳性面积,这可能通过触发免疫原性细胞死亡(ICD)来抑制肿瘤的生长。此外,4-Deo减少了CSF1R的阳性面积,抗肿瘤作用可能通过阻断肿瘤相关巨噬细胞(TAMs)向M2表型的转化来实现。
■总之,本文证明了4-Deo在体外和体内治疗癌症的前景。本文为4-Deo的研究奠定了基础,有利于进一步开发以4-Deo为先导化合物的抗肿瘤药物。
UNASSIGNED: Anthraquinone drugs are widely used in the treatment of tumors. However, multidrug resistance and severe cardiac toxicity limit its use, which have led to the discovery of new analogues. In this paper, 4-Deoxy-ε-pyrromycinone (4-Deo), belonging to anthraquinone compounds, was first been studied with the anti-tumor effects and the safety in vitro and in vivo as a new anti-tumor drug or lead compound.
UNASSIGNED: The quantitative analysis of 4-Deo was established by UV methodology. The anti-cancer effect of 4-Deo in vitro was evaluated by cytotoxicity experiments of H22, HepG2 and Caco2, and the anti-cancer mechanism was explored by cell apoptosis and cycle. The tumor-bearing mouse model was established by subcutaneous inoculation of H22 cells to evaluate the anti-tumor effect of 4-Deo in vivo. The safety of 4-Deo was verified by the in vitro safety experiments of healthy cells and the in vivo safety experiments of H22 tumor-bearing mice. Tumor tissue sections were labeled with CRT, HMGB1, IL-6 and CD115 to explore the preliminary anti-cancer mechanism by immunohistochemistry.
UNASSIGNED: In vitro experiments demonstrated that 4-Deo could inhibit the growth of H22 by inducing cell necrosis and blocking cells in S phase, and 4-Deo has less damage to healthy cells. In vivo experiments showed that 4-Deo increased the positive area of CRT and HMGB1, which may inhibit tumor growth by triggering immunogenic cell death (ICD). In addition, 4-Deo reduced the positive area of CSF1R, and the anti-tumor effect may be achieved by blocking the transformation of tumor-associated macrophages (TAMs) to M2 phenotype.
UNASSIGNED: In summary, this paper demonstrated the promise of 4-Deo for cancer treatment in vitro and in vivo. This paper lays the foundation for the study of 4-Deo, which is beneficial for the further development anti-tumor drugs based on the lead compound of 4-Deo.